TGTX
NasdaqTG THERAPEUTICS, INC.
Basic Materials · Pharmaceutical Preparations
Research view
Fundamentals · SEC EDGAR · FY 2025-12-31
Revenue & Earnings — fiscal year
🔒 price chart needs market-data feed$6.7M
2021
$2.8M
2022
$233.7M
2023
$329.0M
2024
$616.3M
2025
Snapshot
SEC EDGAR · FY 2025-12-31Revenue$616.3M
Net Income$447.2M
Gross Profit—
Oper Income$123.3M
EPS (dil)$2.77
Rev/sh$4.03
FCF/sh$-0.16
Book/sh$4.23
Gross M—
Oper M20.0%
Profit M72.6%
FCF M-4.1%
ROE69.0%
ROA42.1%
ROIC63.2%
R&D/Rev26.0%
Rev Y/Y87.3%
Rev 3Y CAGR504.9%
EPS Y/Y1746.7%
EPS 3Y CAGR—
FCF 3Y CAGR—
Payout—
Div/sh—
Shs Chg Y/Y+0.7%
Current Ratio4.10
Quick Ratio3.29
Debt/Eq0.38
Int Coverage4.6×
Net Debt$165.2M
Total Debt$245.6M
Cash & Eq$80.5M
Total Assets$1.1B
Oper CF$-24.8M
Capex$214,000
Free CF$-25.0M
Buybacks$0
Equity$648.0M
Liabilities$415.2M
Shs Outstand0.15B
SectorBasic Materials
🔒 P/E—
🔒 Fwd P/E—
🔒 P/S—
🔒 P/B—
🔒 Market Cap—
🔒 Div Yield—
🔒 52W Range—
🔒 Beta—
40+ fundamentals — free from SEC EDGAR (public domain). Only the 🔒 price-derived column needs a market-data feed.
Financials — annual
SEC EDGAR · last 5 FY| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $6.7M | $2.8M | $233.7M | $329.0M | $616.3M |
| Gross Profit | — | — | — | — | — |
| Operating Income | $-344.8M | $-218.3M | $20.6M | $41.9M | $123.3M |
| Net Income | $-348.1M | $-198.3M | $12.7M | $23.4M | $447.2M |
| Diluted EPS | $-2.63 | $-1.65 | $0.09 | $0.15 | $2.77 |
| Operating Cash Flow | $-295.6M | $-176.2M | $-31.4M | $-40.5M | $-24.8M |
| Free Cash Flow | $-296.0M | $-176.2M | $-31.4M | $-40.6M | $-25.0M |
COMMUNITY · $TGTX0 theses
POST YOUR TAKE →Fundamentals sourced from SEC EDGAR filings (public domain). For informational purposes only. Not investment advice.